Clinical Genetics · Philadelphia, PA
NPI
1811152796
Since 2008
Specialty
Clinical Genetics
Code 207SG0201X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3400 Civic Center Blvd., 1st Floor
Philadelphia, PA, 19104
Phone (215) 662-2454
Groups this clinician bills Medicare through
Medicare paid, 2024
$8,064
91 services
Medicare patients, 2024
52
Average age 64
Drug cost, 2024
$3.3M
111 prescriptions
Company payments, 2025
$60K
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Staci M Kallish was code 99215 (office e&m - established), 29 times for 22 patients. In total Staci M Kallish billed 91 services in 5 codes, and Medicare paid $8,064.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 29 | 22 | $116.72 | $3,385 |
| 99205 Office E&M - New | Facility | 27 | 27 | $137.37 | $3,709 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 22 | 19 | $13.33 | $293 |
By year: 2022 $6,327 for 50 services; 2023 $7,157 for 60 services; 2024 $8,064 for 91 services.
Medicare prescription drug claims, 2024
In 2024, the drug Staci M Kallish prescribed most often to Medicare patients was Fabrazyme (Agalsidase Beta), with 26 prescriptions and refills. In total Staci M Kallish wrote 111 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Fabrazyme Agalsidase Beta | 26 | 26 | Under 11 | $748K |
| Cerdelga Eliglustat Tartrate | 22 | 22 | Under 11 | $709K |
| Galafold Migalastat Hcl | 18 | 22 | Under 11 | $549K |
| Cerezyme Imiglucerase | 14 | 14 | Under 11 | $441K |
| Sapropterin Dihydrochloride Generic | 12 | 12 | Under 11 | $129K |
Brand drugs: 93 claims; generic drugs: 18 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Staci M Kallish $60K ($60K in general payments such as food, travel and fees) from 4 companies. The largest payer was Amicus Therapeutics, Inc. with $43K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.